Date:6/9/2011

contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

pTeroPure Contact:
Jeremy Bartos
Product Development Manager
949-600-9694
jeremyb@pteropure.com

ChromaDex Media Inquiries:
Carolyn Hawley
Canale Communications
619-849-5375
carolyn@canalecomm.com

University of Mississippi Contact:
Mitchel Diggs
Associate Director
Media and Public Relations
662-915-5639
mdiggs@olemiss.edu

'/>"/>

SOURCE ChromaDex Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Life Extension® Launches New Product Containing ChromaDexs pTeroPure® Pterostilbene
2. Nutraceutical International Corporation Launches Product Featuring ChromaDexs pTeroPure™ Pterostilbene
3. ChromaDex and Bruker Optics Sign Agreement to Expedite Dietary Supplement Testing for Compliance With FDA Good Manufacturing Practice Requirements
4. ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
5. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
6. Biomerix Awarded Two Device Licenses by Health Canada
7. China Sky One Medical Obtains Production Licenses for Thirteen New Medical Products
8. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
9. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
10. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
11. Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries